Metrics as of 10/16/2026, 11:12 AM (Berlin time), refresh in progress.
Kestra Medical Technologies Stock
Kestra Medical Technologies, Ltd.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Brian Webster
- Employees
- 443
- Market cap
- $1.7 B
- IPO
- 06/03/2025
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. The core mission of the company is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. Its…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Kestra Medical Technologies stock: price history
1D
+12.6%
1W
+11.3%
1M
+13.9%
6M
+40.5%
YTD
+8.1%
1Y
+24.7%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
10/12/2026 (in 54 days)
Volatility around earnings
~19% stronger price swings than usual
Kestra Medical Technologies stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 01/09/2026.
Ask the agents about Kestra Medical Technologies
Analyst assessment of Kestra Medical Technologies
PRICE TARGET LOW
US$30.00
CONSENSUS
US$30.67
MEDIAN
US$30.00
PRICE TARGET HIGH
US$32.00
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 15/09/2026
Kestra Medical Technologies stock metrics
P/E
-10.74
P/B
7.55
EV/EBITDA
-13.13
RETURN ON EQUITY
-19.8%
NET MARGIN
-142.3%
DEBT/EQUITY
0.34
DIVIDEND YIELD
0.0%
AS OF
31/07/2026
Free float & liquidity
FREE FLOAT
56.6%
FLOAT SHARES
33,702,446
AVG. DAILY VOLUME (30D)
378,558
Insider transactions (SEC)
COHEN RAYMOND W
Kwo Elizabeth
Reilly Kevin C
Reilly Kevin C
Ladone Mary Kay
Attention
Price since yesterday: +12.6%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Kestra Medical Technologies stock
What does Kestra Medical Technologies do?
Kestra Medical Technologies, Ltd. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Brian Webster, the company employs around 443 people.
The IPO was on 06/03/2025; the stock trades on NASDAQ under the ticker KMTS.
What do analysts say about Kestra Medical Technologies stock?
4 analysts rate the stock, the consensus is Buy (as of 15/09/2026).
The average price target is US$30.67, ranging from US$30.00 to US$32.00, with a median of US$30.00.
This is an external assessment, not a statement by Market Jury.
When does Kestra Medical Technologies report next?
The next earnings date is 10/12/2026.
Around past earnings, price swings were roughly 19% stronger than usual.
Does Kestra Medical Technologies pay a dividend?
No, Kestra Medical Technologies currently does not pay a dividend.
Which stocks are comparable to Kestra Medical Technologies?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get Kestra Medical Technologies stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kestra Medical Technologies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.